Share this article
Share this article
WASHINGTON, Dec. 11, 2020 /PRNewswire/ The leaders of 18 pharmacy organizations today issued the following statement following the Food and Drug Administration s approval of the first Emergency use Authorization for the COVID-19 vaccine. We heartily welcome the decision by the US Food and Drug Administration (FDA) to authorize the emergency use of the first COVID-19 vaccine, following the recommendation of the Vaccines and Related Biological Products Advisory Committee (VRBPAC). This is a historic moment in the nation s effort to end the pandemic. The pharmacy profession is ready to do its part as qualified, active participants in administering these vaccines in accordance with guidance issued by the FDA, CDC, HHS and state and local health departments, as well as increasing access for the American public to these important disease prevention tools.
VANCOUVER, BC / ACCESSWIRE / December 10, 2020 / NeutriSci International Inc.
( NeutriSci or the Company )
(TSX-V:NU) (OTCQB:NRXCF) (FRANKFURT:1N9), an innovative technology company developing products for the nutraceutical industry, is pleased to provide an update on the latest developments with its US manufacturing and distribution partner, Cryopharm Corp. (
Cryopharm ).
Washington State
The Department of Agriculture in the State of Washington has given its approval for the manufacturing, distribution and sale of the entire Cryopharm product line which is powered by NeutriSci s ingredients and technology. The approved products include Marbl Melts™, Kali Juice™, Café Maria as well NeutriSci s Kushtabs™ and Zenstix™. Distribution and sales of the products are expected to start in Q1/2021. The products will be dispensed in approximately 400 locations across the State of Washington.